Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.
作者信息
Muir Kate-Lynn, Kallam Avyakta, Koepsell Scott A, Gundabolu Krishna
机构信息
University of Nebraska Medical Center, Omaha, NE.
University of Nebraska Medical Center, Omaha, NE
出版信息
N Engl J Med. 2021 May 20;384(20):1964-1965. doi: 10.1056/NEJMc2105869. Epub 2021 Apr 14.
Abstract
摘要
相似文献
1
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.Ad26.COV2.S疫苗接种后血栓性血小板减少症
N Engl J Med. 2021 May 20;384(20):1964-1965. doi: 10.1056/NEJMc2105869. Epub 2021 Apr 14.
2
Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism.一名表现为急性静脉血栓栓塞的男性在接种Ad26.COV2.S疫苗后出现疫苗诱导的血栓性血小板减少症。
Am J Hematol. 2021 Sep 1;96(9):E346-E349. doi: 10.1002/ajh.26265. Epub 2021 Jun 17.
3
Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy.Ad26.COV2.S疫苗接种后出现血小板减少症和内脏血栓形成，经颈静脉肝内门体分流术和血栓切除术成功治疗。
Am J Hematol. 2021 Sep 1;96(9):1180-1182. doi: 10.1002/ajh.26258. Epub 2021 Jun 14.
4
Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.2020 年 12 月至 2021 年 8 月美国 COVID-19 疫苗接种后血栓性血小板减少综合征病例系列报告。
Ann Intern Med. 2022 Apr;175(4):513-522. doi: 10.7326/M21-4502. Epub 2022 Jan 18.
5
Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US.接种 Ad26.COV2.S 后发生致命性疫苗诱导的免疫性血栓性血小板减少症（VITT）：首例美国以外的确诊病例。
Infection. 2022 Apr;50(2):531-536. doi: 10.1007/s15010-021-01712-8. Epub 2021 Oct 9.
6
Activation of coagulation and proinflammatory pathways in thrombosis with thrombocytopenia syndrome and following COVID-19 vaccination.血栓性血小板减少性综合征伴 COVID-19 疫苗接种后凝血和促炎途径的激活。
Nat Commun. 2023 Oct 23;14(1):6703. doi: 10.1038/s41467-023-42559-x.
7
Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data.接种 BNT162b2、ChAdOx1 nCoV-19 和 Ad26.COV2.S 疫苗后的心血管、神经和肺部事件：欧洲数据分析。
J Autoimmun. 2021 Dec;125:102742. doi: 10.1016/j.jaut.2021.102742. Epub 2021 Oct 26.
8
Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination.接种 Ad26.COV2.S 疫苗后，比伐卢定治疗血栓性血小板减少性紫癜和脑静脉窦血栓形成的早期结果。
Ann Emerg Med. 2021 Oct;78(4):511-514. doi: 10.1016/j.annemergmed.2021.04.035. Epub 2021 Jul 3.
9
Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.血栓性血小板减少性综合征：Ad26.COV2.S 的临床试验和上市后经验的数据库综述
Vaccine. 2023 Aug 23;41(37):5351-5359. doi: 10.1016/j.vaccine.2023.07.013. Epub 2023 Jul 28.
10
Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia.针对 COVID-19 疫苗的罕见不良反应：从过敏反应到血栓和血小板减少症。
Int Rev Immunol. 2022;41(4):438-447. doi: 10.1080/08830185.2021.1939696. Epub 2021 Jul 12.
引用本文的文献
1
Epidemiology of Thrombotic Thrombocytopenia Syndrome 2011 to 2022: English Sentinel Network Cohort Studies.2011年至2022年血栓性血小板减少综合征的流行病学：英文哨点网络队列研究。
Drug Saf. 2025 Oct;48(10):1161-1175. doi: 10.1007/s40264-025-01566-1. Epub 2025 Jul 31.
2
Anti-PF4 mediated thrombocytopenia and thrombosis associated with acute cytomegalovirus infection displays both HIT-like and VITT-like characteristics.抗PF4介导的血小板减少症和与急性巨细胞病毒感染相关的血栓形成表现出类似肝素诱导的血小板减少症（HIT）和疫苗诱导的免疫性血小板减少症（VITT）的特征。
Br J Haematol. 2025 Jun;206(6):1737-1742. doi: 10.1111/bjh.20092. Epub 2025 Apr 29.
3
The seroprevalence of adenoviruses since 2000.2000年以来腺病毒的血清流行率。
Emerg Microbes Infect. 2025 Dec;14(1):2475831. doi: 10.1080/22221751.2025.2475831. Epub 2025 Mar 17.
4
Mini-clusters of postadenovirus VITT.腺病毒后疫苗诱导的血小板减少症的微型聚集物
Res Pract Thromb Haemost. 2024 Nov 26;9(1):102641. doi: 10.1016/j.rpth.2024.102641. eCollection 2025 Jan.
5
Absence of platelet overactivation and thrombosis formation among patients with coronary atherosclerosis disease after vaccination against SARS-CoV-2.接种SARS-CoV-2疫苗后冠心病患者血小板过度活化及血栓形成情况的缺失
Heliyon. 2024 Sep 29;10(20):e38336. doi: 10.1016/j.heliyon.2024.e38336. eCollection 2024 Oct 30.
6
Prothrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19.针对重症 COVID-19 中刺突蛋白受体结合域的促血栓形成抗体。
Blood. 2025 Feb 6;145(6):635-647. doi: 10.1182/blood.2024025010.
7
Bridging gene therapy and next-generation vaccine technologies.连接基因治疗与下一代疫苗技术。
Gene Ther. 2025 Jan;32(1):4-7. doi: 10.1038/s41434-024-00502-9. Epub 2024 Nov 18.
8
A SONAR report on Nirmatrelvir/ritonavir-associated rebound COVID-19: Using new databases for evaluating new diseases.关于尼马曲韦/利托那韦相关复阳 COVID-19 的一份超声报告：利用新数据库评估新发疾病。
PLoS One. 2024 Sep 25;19(9):e0308205. doi: 10.1371/journal.pone.0308205. eCollection 2024.
9
Cardiac and Neurological Complications Post COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series.新冠疫苗接种后的心脏和神经并发症：病例报告和病例系列的系统评价
Vaccines (Basel). 2024 May 24;12(6):575. doi: 10.3390/vaccines12060575.
10
The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies.免疫系统——腺病毒疗法的双刃剑。
Viruses. 2024 Jun 17;16(6):973. doi: 10.3390/v16060973.
本文引用的文献
1
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.接种 ChAdOx1 nCov-19 疫苗后发生血栓性血小板减少症。
N Engl J Med. 2021 Jun 3;384(22):2092-2101. doi: 10.1056/NEJMoa2104840. Epub 2021 Apr 9.
2
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.ChAdOx1新冠疫苗接种后的血栓形成和血小板减少症
N Engl J Med. 2021 Jun 3;384(22):2124-2130. doi: 10.1056/NEJMoa2104882. Epub 2021 Apr 9.
3
High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review.大剂量静脉注射免疫球蛋白治疗和预防肝素诱导的血小板减少症：综述。
Expert Rev Hematol. 2019 Aug;12(8):685-698. doi: 10.1080/17474086.2019.1636645. Epub 2019 Jul 5.
4
Autoimmune heparin-induced thrombocytopenia.自身免疫性肝素诱导的血小板减少症。
J Thromb Haemost. 2017 Nov;15(11):2099-2114. doi: 10.1111/jth.13813. Epub 2017 Sep 28.
Zotero 插件